合同开发与制造组织CordenPharma达成收购AmbioPharm的协议，以扩大全球肽API产能-动脉网

CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity

CISION 等信源发布 2026-05-27 13:00



可切换为仅中文







Acquisition strengthens U.S. peptide manufacturing capabilities

收购加强了美国的肽制造能力

and broadens global expertise in complex peptide APIs

并拓宽了全球在复杂肽类活性药物成分方面的专业知识

CordenPharma has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide CDMO with facilities in North Augusta, South Carolina (USA) and Shanghai (China).

CordenPharma 已达成协议，收购总部位于美国的肽类 CDMO 公司 AmbioPharm，该公司在南卡罗来纳州北奥古斯塔（美国）和上海（中国）设有设施。

With the acquisition, CordenPharma broadens its peptide API development and manufacturing capabilities for complex peptide programs.

通过此次收购，CordenPharma 拓展了其在复杂肽项目方面的肽API开发和制造能力。

The transaction expands CordenPharma's upstream and downstream peptide manufacturing footprint by adding further capacity for U.S.-based peptide API supply and bringing Shanghai-based production options into its network for global customers.

该交易通过增加美国肽类原料药供应的产能，并将上海的生产选项纳入其面向全球客户的网络，扩大了CordenPharma在上下游肽类制造领域的版图。

The deal bolsters CordenPharma's peptide CDMO capabilities, giving customers broader choices in manufacturing lines, scale-up path and regional / global supply models.

该交易增强了CordenPharma的肽CDMO能力，使客户在生产线、规模扩展路径以及区域/全球供应模式上有更广泛的选择。

BASEL, Switzerland

瑞士巴塞尔

，

May 27, 2026

2026年5月27日

/PRNewswire/ -- CordenPharma, a leading global Contract Development and Manufacturing Organization (CDMO), today announces that it has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide API CDMO.

/PRNewswire/ -- 全球领先的合同开发和制造组织（CDMO）CordenPharma今天宣布，已达成协议收购总部位于美国的肽类API CDMO公司AmbioPharm。

Adding complementary peptide API capabilities

添加互补的肽类API功能

继续阅读

(AmbioPharm Photos) - CordenPharma to Acquire AmbioPharm’s two peptide API manufacturing facilities in North Augusta, South Carolina, USA and Shanghai, China.

（AmbioPharm照片）- CordenPharma将收购AmbioPharm位于美国南卡罗来纳州北奥古斯塔和中国上海的两家肽类API制造工厂。

With its two sites in South Carolina (USA) and Shanghai (China), AmbioPharm adds differentiated peptide manufacturing capabilities to CordenPharma's existing Peptides Platform and expertise. Once combined, these will include advanced linear and fragment-based peptide approaches supported by flexible Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), and hybrid synthesis, as well as CordenPharma's Tag-Assisted Peptide Synthesis (TAPS).

通过其位于美国南卡罗来纳州和中国上海的两个基地，AmbioPharm为CordenPharma现有的多肽平台和专业知识增添了差异化的多肽生产能力。一旦结合，这些能力将包括由灵活的固相多肽合成（SPPS）、液相多肽合成（LPPS）及混合合成支持的先进线性与片段化多肽方法，以及CordenPharma的标签辅助多肽合成（TAPS）。

Following closing, the acquisition will give customers flexible options to match their specific manufacturing requirements for complex, long and high-purity peptide APIs..

收购完成后，将为客户提供灵活的选择，以满足其对复杂、长链和高纯度肽类原料药的特定生产需求。

Scaling CordenPharma's facility network

扩展科登制药的设施网络

AmbioPharm employs approximately 400 people across its two sites. The acquisition builds on CordenPharma's global facility network of 11 sites in Europe and North America by expanding its U.S. peptide manufacturing capacity and bringing Shanghai-based peptide supply into its operational footprint.

AmbioPharm 在其两个基地共雇用了大约 400 名员工。此次收购扩展了 CordenPharma 在欧美地区的 11 个全球设施网络，通过扩大其美国的肽类生产能力，并将位于上海的肽类供应纳入其运营范围。

As CordenPharma's second U.S. peptide facility, the acquisition of AmbioPharm's North Augusta, SC site will add significant capacity focused on purification and lyophilization of peptide APIs. The acquisition will complement existing capabilities in CordenPharma Colorado (US), allowing CordenPharma to deliver fully U.S.-based peptide API supply options to meet customer needs for large-scale commercial peptide projects..

作为CordenPharma在美国的第二家肽类设施，收购AmbioPharm位于南卡罗来纳州北奥古斯塔的工厂将增加专注于肽类活性药物成分（API）纯化和冻干的显著产能。此次收购将补充CordenPharma科罗拉多（美国）现有的能力，使CordenPharma能够提供完全基于美国的肽类API供应选项，以满足客户对大规模商业肽项目的需求。

At AmbioPharm's Shanghai campus, CordenPharma will leverage the new state-of-the-art peptide manufacturing facility to support clinical and commercial global peptide supply with significant upstream capacity across SPPS, LPPS and hybrid synthesis, as well as selected downstream capabilities.

在安必欧制药的上海园区，科登制药将利用全新的尖端肽制造设施，通过固相肽合成、液相肽合成和混合合成的显著上游产能，以及特定的下游能力，来支持临床和全球商业肽供应。

Expanding CordenPharma's global peptide CDMO capabilities

扩大CordenPharma的全球肽CDMO能力

By integrating the North Augusta and Shanghai sites, CordenPharma expands its global Peptides Platform across three continents, offering customers end-to-end peptide development and manufacturing support.

通过整合北奥古斯塔和上海的工厂，CordenPharma 将其全球多肽平台扩展到三大洲，为客户提供端到端的多肽开发和生产支持。

Since CordenPharma was acquired by Astorg in 2022, the company has continued to expand its global peptide platform through strategic investments and expanded manufacturing capacity. As part of the transaction, AmbioPharm's shareholders will reinvest into the combined business. This reinvestment reflects shareholders' confidence in the capabilities and long-term growth potential of the expanded Peptides Platform.

自2022年CordenPharma被Astorg收购以来，该公司通过战略投资和扩大生产能力持续扩展其全球多肽平台。作为交易的一部分，AmbioPharm的股东将重新投资合并后的企业。这一再投资反映了股东对扩展后的多肽平台能力及长期增长潜力的信心。

The transaction remains subject to customary closing conditions. Financial terms have not been disclosed..

该交易仍需满足惯例的交割条件，财务条款尚未披露。

Dr. Michael Quirmbach, President & CEO of CordenPharma Group, commented: 'This acquisition significantly bolsters CordenPharma's Peptides Platform with complementary capabilities and advances our strategic objective to serve as a leading peptide manufacturing partner. As peptide programs become more complex and advanced, customers value CDMO partners who can offer both upstream scientific route selection and process robustness with downstream manufacturing scale and built-in geographic flexibility.

CordenPharma集团总裁兼首席执行官迈克尔·奎尔巴赫博士评论道：“此次收购显著增强了CordenPharma的多肽平台的能力，并推动了我们成为领先的多肽制造合作伙伴的战略目标。随着多肽项目变得越来越复杂和先进，客户更加重视能够提供上游科学路线选择和工艺稳健性，同时具备下游生产规模和内置地理灵活性的CDMO合作伙伴。”

AmbioPharm's capabilities perfectly complement our existing peptide expertise, helping us to broaden the ways we support customers from development to commercialization.'.

AmbioPharm 的能力完美地补充了我们现有的肽专业知识，帮助我们拓宽了从开发到商业化的客户支持方式。

'Becoming part of CordenPharma marks an exciting new chapter for AmbioPharm. Together, we will be able to offer customers broader technical capabilities, increased global capacity, and a highly reliable Peptides Platform to support the development and commercialization of peptide-based medicines, delivered through a fully-integrated global facility network.

“成为CordenPharma的一部分标志着AmbioPharm令人兴奋的新篇章。我们将能够为客户提供更广泛的技术能力、增加的全球产能，以及一个高度可靠的多肽平台，以支持基于多肽的药物的研发和商业化，并通过完全集成的全球设施网络来实现交付。”

Importantly, we remain focused on the patients who rely on these medicines,' said AmbioPharm CEO Brian Gregg..

“重要的是，我们仍然专注于依赖这些药物的患者，”AmbioPharm 首席执行官 Brian Gregg 表示。

'This acquisition marks an important step in CordenPharma's growth journey, enhancing the company's strategic positioning and supporting significant long-term growth opportunities in peptides,' said Astorg Director Antoine Thomas. CordenPharma's Chairman of the Board, Paul Perreault, commented, 'This is an exciting time for the promise of peptides to help patients across the globe, and now at CordenPharma we strengthen our capabilities to deliver this promise for our partners.'.

Astorg董事安托万·托马斯表示：“此次收购标志着CordenPharma增长历程中的重要一步，增强了公司的战略定位，并支持了肽类领域的重大长期增长机会。”CordenPharma董事会主席保罗·佩雷ault评论道：“这是一个令人振奋的时刻，肽类有望帮助全球患者，现在在CordenPharma，我们增强了能力，为合作伙伴实现这一承诺。”

'Since our investment in AmbioPharm, we have worked closely with the company as a strategic shareholder to enhance its operations and expand its global footprint. We are incredibly proud of what AmbioPharm has achieved and are very excited about its merger with CordenPharma, given the breadth of its peptides platform and expertise.

“自从我们投资AmbioPharm以来，我们作为战略股东与该公司密切合作，以增强其运营并扩大其全球影响力。鉴于AmbioPharm在多肽平台和专业知识方面的广泛覆盖，我们对其实现的成就感到无比自豪，并对其与CordenPharma的合并感到非常兴奋。

We remain confident in the strong growth potential of the global peptide CDMO market and look forward to continuing to support the combined business as it seeks to achieve the next level of success,' commented Ling Yang, Partner and Head of Healthcare at Carlyle Asia..

凯雷亚洲合伙人兼医疗保健主管杨凌评论道：“我们对全球多肽CDMO市场的强劲增长潜力充满信心，并期待继续支持合并后的业务，助力其迈向下一个成功阶段。”

BNP Paribas acted as exclusive financial advisor to AmbioPharm.

法国巴黎银行担任AmbioPharm的独家财务顾问。

About CordenPharma

关于CordenPharma

CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization..

CordenPharma是一家CDMO合作伙伴，支持复杂模式的生物技术和制药创新者推进其药物开发生命周期。通过其全球一体化设施网络中各团队的集体专业知识，CordenPharma提供定制化的外包服务，涵盖从早期临床阶段开发到商业化的完整供应链。

With scientific expertise and partnership at its core, CordenPharma provides customers with high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid Nanoparticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency)..

以科学专业知识和合作伙伴关系为核心，CordenPharma 为客户提供高价值、端到端的服务，重点关注肽、寡核苷酸、定制脂质辅料、脂质纳米颗粒 (LNPs)、无菌注射剂以及小分子（包括高效和常规效用分子）的广泛供应。

The CordenPharma Group is currently comprised of 11 facilities across Europe and North America. In the 2025 financial year, the organization generated sales of €960 million and had over 3,000 employees. In 2022, CordenPharma was acquired by

CordenPharma集团目前在欧洲和北美拥有11家工厂。在2025财政年度，该组织实现了9.6亿欧元的销售额，并拥有超过3000名员工。2022年，CordenPharma被收购。

Astorg

阿斯托尔格

to accelerate its development and further strengthen its capabilities in the CDMO space.

加快其发展，并进一步加强其在CDMO领域的能力。

Please visit

请访问

cordenpharma.com

for more information I Follow CordenPharma on

欲了解更多信息，请关注CordenPharma

领英

About AmbioPharm

关于AmbioPharm

AmbioPharm is a global custom synthetic peptide CDMO founded in 2005 and headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at clinical and commercial stages. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) under cGMP for clients worldwide.

AmbioPharm 是一家全球定制合成肽 CDMO，成立于 2005 年，总部位于美国南卡罗来纳州北奥古斯塔，专注于为临床和商业阶段的肽类活性药物成分 (API) 开发高效制造工艺。我们在美国南卡罗来纳州和中国上海的制造工厂按照 cGMP 标准为全球客户生产新化学实体 (NCE)。

Both facilities have been inspected multiple times by the FDA as well as other global regulatory bodies with excellent outcomes. Our mission is to accelerate your peptides to patients..

这两个设施都经过了美国食品药品监督管理局（FDA）以及其他全球监管机构的多次检查，结果非常出色。我们的使命是加速将您的肽类药物送达患者手中。

For more information about AmbioPharm:

有关AmbioPharm的更多信息：

www.ambiopharm.com

| Follow AmbioPharm on

| 关注AmbioPharm

领英

About Astorg

关于Astorg

Astorg is a leading pan-European private equity firm with over €24 billion of assets under management. Astorg is a multi-specialist investor with deep expertise in healthcare, technology and business services. Within healthcare, Astorg concentrates on a narrow set of subsectors: pharmaceutical services and technology, MedTech and MedTech services, life science tools, and diagnostics.

Astorg是一家领先的泛欧私募股权公司，管理资产超过240亿欧元。Astorg是多领域专业投资者，在医疗保健、技术和商业服务方面拥有深厚的专业知识。在医疗保健领域，Astorg专注于少数几个子行业：制药服务与技术、医疗技术及医疗技术服务、生命科学工具以及诊断。

Enjoying a distinct entrepreneurial culture, an engaged shareholder perspective and a lean decision making body, Astorg works with founders, entrepreneurs and management teams to acquire premium international B2B businesses, providing them with strategic guidance, governance and capital to enhance their strategic positioning and achieve their financial objectives.

拥有独特的创业文化、积极的股东视角和精简的决策机构，Astorg与创始人、企业家和管理团队合作，收购优质的国际B2B企业，为他们提供战略指导、治理和资本，以提升其战略定位并实现财务目标。

Headquartered in Luxembourg, Astorg has offices in London, Paris, New York, Frankfurt, and Milan..

总部位于卢森堡的阿斯托尔在伦敦、巴黎、纽约、法兰克福和米兰设有办事处。

For more information about Astorg:

有关 Astorg 的更多信息：

www.astorg.com

| Follow Astorg on

| 关注 Astorg

领英

Photo -

照片 -

https://mma.prnewswire.com/media/2988248/CordenPharma_and_AmbioPharm.jpg